PHILADELPHIA — (April 22, 2021) — A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen. A similar vaccine candidate was previously shown to be safe and tolerable with a three-dose intramuscular injection regimen in a recently completed human phase 1 study and is currently in expanded studies of phase 1/2a trial.
New results were published today in JCI Insight.
“While several vaccine products are being advanced against MERS and other coronaviruses, low-dose delivery and shortened regimes are crucial to rapidly induce protective immunity, particularly during emerging outbreaks, as the current SARS-CoV-2 pandemic
Tech Update
At Basis Set Ventures merging venture capital and software development yields a $165 million new fund
MERS DNA vaccine induces immunity, protects from virus challenge in preclinical model
Samsung Galaxy A22 borrows Google’s rear camera design
The Significance Of Doc Version Control
This is your brain on Zoom
Lighting it up: Fast material manipulation through a laser
Google One’s VPN security holds up, according to an audit